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Introduction
Autoinflammatory disorders (AIDs) represent an
expanding group of complex diseases characterized by
periodic or chronic systemic inflammations. Mutations
in more than 15 geneshave been associated with autoin-
flammatory recessive or dominant syndromes. Next
Generation Sequencing (NGS) has emerged in the last
year as new diagnostic tool in this field.
Objectives
To share data obtained by the use of NGS in a cohort of
patients affected by an autoinflammatory disease of
undefined origin evaluated at our center.
Materials and methods
In this study we enrolled 158 patients from 2010 to
2014. We developed NGS starting with 11 genes already
known to be involved in AID (Panel 1: MVK, MEFV,
NRLP12, NRLP3, NOD2, TNFRSF1A and PSTPIP1 and
Panel 2: IL1RN, LPIN2, IL36RN, PSMB8). Targeted
resequencing was performed using customized panel
and analyzed with the MiSeq® sequencing platform
(Illumina, San Diego, CA). All variants identified have
been confirmed by Sanger sequencing.
Results
48,(73%) of the patients present variants in genes of
Panel 1. 32,46% have variants in NLRP3 gene: the most
frequent variants are Q705K (56%) and V200M (32%).
About 26% have variants in NOD2, the most frequent
variant is R702W (25%). 30% have variants in NLRP12,
the most frequent variant is F402L (65%), in two cases
in homozygosity. 23,4% have variants in MEFV, the most
frequent variant is E148Q (22%). 4% have variants in MVK,
V377I (100%). 10,38% have variants in TNFRSF1A, the
most frequent variant is R121Q (75%). 9% have variants in
PSTPIP1. 69% of the patients present variant in only one
gene; 28,57% present variants in two different genes and
two patients in three genes. We performed 15 familial
study to unravel the segregation of some variants.
Conclusion
NGS leads to the identification of many genetic variants
that could be associated with disease susceptibility. The
major challenge is in the interpretation of the clinical rele-
vance of identified variants. Some patients show variants
in multiple analyzed genes: it can be assumed that differ-
ent variants in different genes may cooperate to determine
a pathological phenotype. This will necessitate large-scale
population studies, in vitro functional assay and careful
correlation of genetic information with phenotypic data.
Therefore, close collaboration with clinicians is crucial.
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